ArticleFrontiers in pharmacology2026
Case report: Personalized, response-adapted neoadjuvant alectinib achieves durable remission in stage IIIB ALK-rearranged lung cancer.
Hui Shen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.